ELOXX PHARMACEUTICALS, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
ELOXX PHARMACEUTICALS, INC. (ELOX) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $25.27 million as of 2014-05-16, per its 10-K filed 2016-10-13.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2016-10-13
- 2014-05-16: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $25.27M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|---|---|
| 2014-05-16 | $25.27M 10-K · filed 2016-10-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |